Acute pancreatitis soon after COVID-19 vaccination: A case report : Medicine

Journal Logo

Research Article: Clinical Case Report

Acute pancreatitis soon after COVID-19 vaccination

A case report

Ozaka, Sotaro MDa,∗; Kodera, Takamoto MDb; Ariki, Shimpei MDa; Kobayashi, Takashi MD, PhDc; Murakami, Kazunari MD, PhDa

Editor(s): Saranathan., Maya

Author Information
Medicine 101(2):p e28471, January 14, 2022. | DOI: 10.1097/MD.0000000000028471
  • Open


1 Introduction

Several vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed in response to the coronavirus infectious disease 2019 (COVID-19) global pandemic. These vaccines have proven to be highly effective to prevent COVID-19 in the general population.[1–3] Pfizer's BNT162b2 (Pfizer/BioNTech) is a vaccine based on the SARS-CoV-2 spike-protein mRNA.[4] Common side effects of this vaccine include injection site pain, transient fever, headache, and fatigue.[1,5] Recently, although many infrequent side effects have also been reported, only a few cases of acute pancreatitis have been reported.[6–8] Here, we report a rare case of acute pancreatitis that developed shortly after the first dose of the Pfizer/BioNTech COVID-19 mRNA vaccine (Comirnaty).

2 Case presentation

A 71-year-old woman with a history of hypertension, hyperlipidemia, and cerebral infarction was presented with upper abdominal pain and vomiting. She had no history of alcohol consumption, pancreatitis, or allergic reactions to vaccines. She was on regular medication with rosuvastatin, nifedipine, aspirin, enalapril, levocetirizine, and magnesium oxide, and no drug changes were made in the past 3 years. She has no family history of note.

She had received the first dose of the Pfizer/BioNTech COVID-19 mRNA vaccine 2 days prior to her current presentation. Her blood pressure was 142/86 mmHg, heart rate was 92 bpm, and body temperature was 37.3°C. Intense tenderness was observed in the upper abdomen. Laboratory tests revealed serum amylase, 1043 IU/L (reference range, 44–132); lipase, 383 IU/L (reference range, 17–57); and elastase-1, 2158 ng/dL (reference, <300). Her serum alanine transferase, aspartate transaminase, and γ-glutamyl transpeptidase levels were within normal limits. Furthermore, serum triglyceride level was 55 U/L (reference range, 0–149) and immunoglobulin G4 level was 34 mg/dL (reference range, 4–108) (Table 1). An abdominal computed tomography (CT) scan showed diffuse enlargement of the pancreas with ill-defined parenchymal contours (Fig. 1A) and with fat stranding extending to below the kidneys bilaterally (Fig. 1B). Magnetic resonance cholangiopancreatography revealed no biliary stones or anatomical pancreaticobiliary maljunction (Fig. 2A, B). In addition, the abdominal ultrasound performed before CT scan showed no gallstones. According to the revised Atlanta Classification, the diagnosis of mild acute pancreatitis was made, because there were no local complications or organ failure (Modified Marshall score: 0). The patient was treated with the administration of intravenous antimicrobials, proteolytic enzyme inhibitors, and proton pump inhibitors. On day 4 of hospitalization, her serum amylase level decreased to the normal range. On day 14 of hospitalization, follow-up abdominal CT scan revealed the improvement in the enlargement of the pancreas (Fig. 3). The pancreatitis gradually improved thereafter, and she was discharged home on day 38 of hospitalization. Our patient recovered well, having no symptoms and complications after 3 months of follow-up. In addition, informed consent was obtained from the patient for publication of this case report and any accompanying images.

Table 1 - Laboratory data on admission.
Items Data Reference Items Data Reference Items Data Reference
WBC 14,100/μL 3300–8600 Alb 4.5 g/dL 4.1–5.1 Na 136 mEq/L 138–145
RBC 493 × 104/μL 386 × 104–492 × 104 BUN 13.1 mg/dL 8–20 Cl 100 mEq/L 101–108
Hb 14.8 g/dL 11.6–14.8 Cre 0.57 mg/dL 0.46–0.79 K 3.3 mEq/L 3.6–4.8
Hct 42.8% 35.1–44.4 LDL-C 98 mg/dL 0–139 Ca 8.9 mg/dL 8.7–11.0
MCV 86.8 fL 83.6–98.2 TG 55 U/L 0–149 AMY 1043 IU/L 44–132
MCHC 34.6% 31.7–35.3 AST 26 U/L 13–30 Lipase 383 IU/L 17–57
Plt 19.6 × 104/μL 15.8 × 104–34.8 × 104 ALT 20 U/L 7–23 Elastase-1 2158 ng/dL <300
LDH 306 U/L 124–222 CRP 1.81 mg/dL 0–0.14
COVID-19 Ag 0.22 pg/mL <3.99 γ-GTP 29 U/L 9–32 IgG4 34 mg/dL 4–108
CA19-9 6.5 U/mL <37
γ-GTP = γ-glutamyl transpeptidase, Alb = albumin, AST = aspartate transaminase, BUN = blood urea nitrogen, COVID-19 = coronavirus infectious disease 2019, COVID-19 Ag = coronavirus infectious disease 2019 antigen, AMY = amylase, Cre = creatinine, CRP = C-reactive protein, Hb = hemoglobin, Hct = hematocrit, IgG4 = immunoglobulin G4, LDH = lactate dehydrogenase, LDL-C = low density lipoprotein cholesterol, MCHC = mean corpuscular hemoglobin concentration, MCV = mean corpuscular volume, Plt = platelets, RBC = red blood cell, TG = triglyceride, WBC = white blood cell.

Figure 1:
(A) Computed tomography (CT) scan demonstrating diffuse enlargement of the pancreas and ill-defined parenchymal contours (arrow). (B) CT showed fat stranding extending to below the kidneys bilaterally (arrow).
Figure 2:
Magnetic resonance cholangiopancreatography (MRCP) showed no biliary stones or anatomical pancreaticobiliary maljunction. (A) The biliary system was normal (arrow). (B) The main pancreatic duct was not dilated (arrow). There were no cystic lesions.
Figure 3:
CT scan on day 14 of hospitalization revealed the improvement in the enlargement of the pancreas. CT = Computed tomography.

3 Discussion

We report a case of acute pancreatitis after the first dose of the Pfizer/BioNTech COVID-19 mRNA vaccine. Although there are only a few case reports regarding the development of acute pancreatitis after vaccination against COVID-19, it is extremely important to recognize that acute pancreatitis can develop shortly after COVID-19 vaccination.

The present case developed acute pancreatitis 2 days after the first dose of the COVID-19 vaccine. The patient had no history of alcohol consumption and had no recent changes in her regular oral medication. In addition, hypertriglyceridemia, biliary stones, pancreaticobiliary maljunction, pancreatic tumor, and autoimmune pancreatitis were excluded. Therefore, the COVID-19 vaccine was considered to be involved in the onset of pancreatitis in this case.

Two cases of acute pancreatitis after COVID-19 mRNA vaccine have been reported.[6,7] Both cases were women who had developed pancreatitis within a few days after the first dose of the Pfizer/BioNTech COVID-19 mRNA vaccine. Both cases were mild, and no case of pancreatitis with extensive inflammation, as in this case, has been reported yet. Recently, a case of acute pancreatitis after the second dose of Pfizer/BioNTech COVID-19 mRNA vaccine was also reported.[8] However, this patient had consumed alcohol just before the onset of pancreatitis. Thus, we wonder whether the alcohol consumption rather than administration of COVID-19 mRNA vaccine is the event associated with the development of acute pancreatitis in the report of Walter et al. Although the severity is unknown, the vaccine analysis print based on all spontaneous reports received for the Pfizer/BioNTech COVID-19 mRNA vaccine between December 9, 2020 and September 22, 2021 contains 330,983 reports of side effects, including 1 case of obstructive pancreatitis, 12 cases of pancreatitis, 12 cases of acute pancreatitis, and 1 case of necrotizing pancreatitis.[9] Thus, it is of great importance to recognize that acute pancreatitis can occur after COVID-19 vaccination.

Although the mechanism of vaccine-induced pancreatitis remains unclear, a compelling hypothesis of molecular mimicry (molecular mimicry theory) has recently been proposed.[10–12] According to this theory, cross-reactivity due to the similarity between amino acid sequences of viral and self-antigens leads to tissue damage by the cytotoxic antibodies.[13,14] In support of this hypothesis, antibodies against SARS-CoV-2 spike protein have been reported to be cross-reactive to many human tissue antigens.[15] In addition, Anand et al reported that SARS-CoV-2 evolved its own S1/S2 cleavage site and consequently resembled an identical 8-mer FURIN cleavage peptide on the human epithelial sodium channel α subunit. FURIN is expressed in multiple cell types, including in the intestine, pancreas, and lungs, along with angiotensin converting enzyme 2 and epithelial sodium channel α subunit.[16] Based on these reports, we assumed that COVID-19 mRNA vaccination resulted in an autoimmune response based on molecular mimicry, leading to pancreatic injury. Additionally, given that our patient developed pancreatitis 2 days after vaccination, memory T cells had been sensitized to antigens similar to SARS-CoV-2 before vaccination, because post-vaccination antibody production generally requires several weeks.[17] In addition to pancreatitis, infrequent side effects including myocarditis and Guillain-Barré syndrome that developed after COVID-19 mRNA vaccination have also been reported, and the involvement of molecular mimicry theory has been proposed as a mechanism for their development.[18,19]

In conclusion, we report a case of acute pancreatitis that developed soon after the first dose of COVID-19 vaccination. Although it is difficult to conclude that this case developed acute pancreatitis as a side effect of the COVID-19 mRNA vaccine, it is of great importance to diagnose acute pancreatitis when severe abdominal pain occurs soon after COVID-19 mRNA vaccination.

Author contributions

Conceptualization: Takashi Kobayashi, Kazunari Murakami.

Data curation: Sotaro Ozaka.

Formal analysis: Sotaro Ozaka.

Supervision: Kazunari Murakami.

Writing – original draft: Sotaro Ozaka.

Writing – review & editing: Takamoto Kodera, Shimpei Ariki, Takashi Kobayashi, Kazunari Murakami.


[1]. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603–15.
[2]. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403–16.
[3]. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397:99–111.
[4]. Bongiovanni M, Liuzzi G, Schiavon L, Gianturco L, Giuliani G. Evaluation of the immune response to COVID-19 vaccine mRNA BNT162b2 and correlation with previous COVID-19 infection. J Clin Viol 2021;143:104962.
[5]. Ossato A, Tessari R, Trabucchi C, Zuppini T, Realdon N, Marchesini F. Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: a post-marketing Italian study conducted between 1 January and 28 February 2021. Eur J Hosp Pharm 2021;Online ahead of print.
[6]. Parkash O, Sharko A, Farooqi A, Ying GW, Sura P. Acute pancreatitis: a possible side effect of COVID-19 vaccine. Cureus 2021;13:e14741.
[7]. Cieślewicz A, Dudek M, Krela-Kaźmierczak I, Jabłecka A, Lesiak M, Korzeniowska K. Pancreatic injury after COVID-19 vaccine—a case report. Vaccines (Basal) 2021;9:576.
[8]. Walter T, Connor S, Stedman C, Doogue M. A case of acute necrotising pancreatitis following the second dose of Pfizer-BioNTech COVID-19 mRNA vaccine. Br J Clin Pharmacol 2021;01–2. Online ahead of print.
[9]. COVID-19 mRNA Pfizer-BioNTech Vaccine Analysis Print. All UK Spontaneous Reports Received between 9/12/20 and 21/09/22 for mRNA Pfizer/BioNTech Vaccine Analysis Print. [database online] Available at: Accessed October 3, 2021.
[10]. Segal Y, Shoenfeld Y. Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction. Cell Mol Immunol 2018;15:586–94.
[11]. Rose NR. Molecular mimicry and clonal deletion: a fresh look. J Theor Biol 2015;375:71–6.
[12]. Mazraani M, Barbari A. Anti-coronavirus disease 2019 vaccines: need for informed consent. Exp Clin Transplant 2021;19:753–62.
[13]. Bizjak M, Bruck O, Praprotnik S, Dahan S, Shoenfeld Y. Pancreatitis after human papillomavirus vaccination: a matter of molecular mimicry. Immunol Res 2017;65:164–7.
[14]. Bogdanos DP, Smith H, Ma Y, Baum H, Mieli-Vergani G, Vergani D. A study of molecular mimicry and immunological cross-reactivity between hepatitis B surface antigen and myelin mimics. Clin Dev Immunol 2005;12:217–24.
[15]. Vojdani A, Vojdani E, Kharrazian D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases. Front Immunol 2021;11:617089.
[16]. Anand P, Puranik A, Aravamudan M, Venkatakrishnan AJ, Soundararajan V. SARS-CoV-2 strategically mimics proteolytic activation of human ENaC. Elife 2020;9:e58603.
[17]. Naaber P, Tserel L, Kangro K, et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg Health Eur 2021;10: Online ahead of print.
[18]. Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA vaccines. Circulation 2021;144:471–84.
[19]. Razok A, Shams A, Almeer A, Zahid M. Post-COVID-19 vaccine Guillain-Barré syndrome; first reported case from Qatar. Ann Med Surg (Lond) 2021;67:102540.

acute pancreatitis; case report; COVID-19; vaccine

Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.